BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8758470)

  • 1. [In vitro activity of a new fluoroquinolone, marbofloxacin (RO 09-1168) against strictly anaerobic bacteria and some bacteria from human fecal flora].
    Dubreuil L; Houcke I; Leroy I
    Pathol Biol (Paris); 1996 May; 44(5):333-6. PubMed ID: 8758470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of E-4868, a new fluoroquinolone with a 7-azetidin ring, compared with ciprofloxacin, ofloxacin and fleroxacin.
    Mirelis B; Navarro F; Miró E; Coll R; Xicota MA; Prats G
    Drugs Exp Clin Res; 1995; 21(4):129-38. PubMed ID: 8529525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro antibacterial activity of lomefloxacin, a new fluoroquinolone, against hospital strains. Results of a multicenter study].
    Soussy CJ; Le Van Thoi J; Morel C; Acar JF; Thabaut A; Fleurette J; Vallée E; Dabernat H; Chanal M; Drugeon H
    Pathol Biol (Paris); 1990 May; 38(5):390-6. PubMed ID: 2195448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro activity of roxithromycin, new semisynthetic macrolide against obligate anaerobes].
    Dubreuil L; Devos J; Romond C; Bryskier A
    Pathol Biol (Paris); 1986 May; 34(5):440-4. PubMed ID: 3534717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sensitivity of obligate anaerobes to ofloxacin, pefloxacin, enoxacin and norfloxacin].
    Dubreuil L; Devos J; Romond C; Bryskier A
    Pathol Biol (Paris); 1985 May; 33(5):421-5. PubMed ID: 3162143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative antibacterial activity of cefpodoxime, cefuroxime and cefaclor against strict anaerobic bacteria].
    Dubreuil L; Derriennic M; Sedallian A
    Pathol Biol (Paris); 1990 May; 38(5):343-6. PubMed ID: 2367150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The comparative activity of twelve 4-quinolone antimicrobials against gram-positive and gram-negative anaerobes.
    Robbins MJ; O'Hare MD; Felmingham D; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(7):431-4. PubMed ID: 3836865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.
    Fung-Tomc J; Minassian B; Kolek B; Washo T; Huczko E; Bonner D
    J Antimicrob Chemother; 2000 Apr; 45(4):437-46. PubMed ID: 10747819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria.
    Edlund C; Sabouri S; Nord CE
    Eur J Clin Microbiol Infect Dis; 1998 Mar; 17(3):193-5. PubMed ID: 9665302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.
    Citron DM; Appleman MD
    Antimicrob Agents Chemother; 2001 Jan; 45(1):345-8. PubMed ID: 11120995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.
    Wexler HM; Molitoris E; Reeves D; Finegold SM
    J Antimicrob Chemother; 1994 Oct; 34(4):579-84. PubMed ID: 7868409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.
    Goldstein EJ; Citron DM
    Antimicrob Agents Chemother; 1992 May; 36(5):1158-62. PubMed ID: 1324640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The frequency of in vitro resistance to fluoroquinolones among clinical isolates of Escherichia coli.
    Poiată A; Bădicuţ I; Grigore L; Buiuc D
    Roum Arch Microbiol Immunol; 2000; 59(1-2):63-9. PubMed ID: 11845477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria.
    MacGowan AP; Bowker KE; Holt HA; Wootton M; Reeves DS
    J Antimicrob Chemother; 1997 Oct; 40(4):503-9. PubMed ID: 9372419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibility of anaerobes to quinolones in the United States.
    Hecht DW; Wexler HM
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S2-8. PubMed ID: 8953099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ["In vitro" activity of ten antimicrobial agents against anaerobic bacteria. A collaborative study, 1999-2002].
    Litterio M; Bianchini H; Carloni G; Di Martino A; Fernández Canigia L; Greco G; Legaria C; Rollet R; Rossetti A; Predari SC; Castello L
    Rev Argent Microbiol; 2004; 36(3):130-5. PubMed ID: 15559195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.
    Nord CE; Lindmark A; Persson I
    Eur J Clin Microbiol Infect Dis; 1993 Aug; 12(8):640-2. PubMed ID: 8223667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro activity of temafloxacin against anaerobic bacteria: a comparative study.
    Finegold SM; Molitoris E; Reeves D; Wexler HM
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():25-30. PubMed ID: 1664827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of faecal and optimal growth conditions on in vitro pharmacodynamic activity of marbofloxacin against Escherichia coli.
    Pellet T; Gicquel-Bruneau M; Sanders P; Laurentie M
    Res Vet Sci; 2006 Jun; 80(3):324-35. PubMed ID: 16126240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of activities of trovafloxacin (CP-99,219) and five other agents against 585 anaerobes with use of three media.
    Hecht DW; Osmolski JR
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S44-50. PubMed ID: 8953106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.